According to our previous in vitro studies, TSPCs show immunomodulatory capacity to suppress stimulated T cells and the ability to degrade the nociceptive stimulator substance P that is produced in the early phases of tendinopathy [45,46]. This evidence concerns the gene TAC1 and disease of the tendon.